Duncan Moore, BSc PhD – Chairman
Duncan is a Life Sciences industry expert. He is a partner of East West Capital and an adviser to Ondra Partners. Prior to that he was a Managing Director at Morgan Stanley International where he was Global Head of Healthcare Research. During this time he led the equity market positioning of a number of major healthcare companies including Wellcome Plc, Sulzer Medica, Almirall and Grupo Rovi. He trained as a biochemist at the University of Leeds and has a PhD from the University of Cambridge. Whilst at Cambridge he co-founded a molecular diagnostics company with two colleagues. Following his move to the Capital Markets in 1985 he was involved in setting up the Bank Invest BioVenture funds and sat on the Board of these funds until they were sold in 2009. Duncan joined the Lamellar Board in December 2012 and was then appointed Chairman.
Alec McLean, BSc PhD – CEO
Alec has more than 30 years’ experience in respiratory research covering 9 years basic clinical pulmonary research at Edinburgh University Medical School, 9 years drug development with Astra Pharmaceuticals and 14 years in the CRO industry at Quintiles. This included extensive Phase 1-4 global clinical drug development, as Senior Director for global Allergy and Respiratory project management as well as commercial input, product development strategy and product and company due diligence. At any one point in time the value of the studies he had P&L responsibility for exceeded $300m, with yearly sales typically around $100m. Alec delivered pivotal studies for a range of pharma companies from blue chip e.g. Roche, AZ, Merck, Novartis and J&J to emerging biotechs e.g. Vertex, Stallergenes and Inspire.